Latest Market News

Acorn Capital Investment Fund’s shares were suspended following a late submission of its January 2025 Net Tangible Asset Statement, attributed to human error. The company has assured shareholders the issue is resolved and trading resumed promptly.

HiTech Group Australia Limited has reported a robust half-year performance with a 29% increase in net profit and a strategic focus on high-margin ICT services amid growing market demand.

Kina Securities confirms its 2024 underlying profit guidance amid a non-cash statutory profit reduction driven by deferred tax asset adjustments and a customer fraud impact.

QMines Limited has raised $6 million through a strongly supported placement, positioning the company to accelerate exploration and development at its Mt Chalmers and Develin Creek copper and gold projects.

Future Metals NL has addressed an ASX price query by confirming the release of drilling results from its Eileen Bore Prospect, attributing recent trading activity to investor anticipation and compliance with disclosure rules.

Future Metals NL has confirmed a significant copper-nickel mineralised intrusion extending 4.5km at its Eileen Bore Prospect, marking a major step forward in its exploration campaign.

Althea Group Holdings has raised $4 million through a share and loan note placement to boost its THC beverage production and infrastructure across North America, targeting rapid growth in the U.S. and Canada.

The Star Entertainment Group has received a $650 million debt refinancing proposal from Oaktree Capital Management, offering a potential boost to its liquidity but shadowed by significant conditions and uncertainty.

Winsome Resources has raised approximately A$7.8 million through a placement to advance its flagship Adina Lithium Project and extend the Renard Option to August 2025, with plans for an additional share purchase plan targeting A$2.5 million.

PYC Therapeutics has launched a A$145.8 million pro-rata accelerated non-renounceable entitlement offer to fund late-stage clinical trials across its pipeline targeting rare diseases with high unmet needs. The capital raise aims to extend the company’s cash runway beyond FY27, supporting four drug candidates through critical human safety and efficacy milestones.

PYC Therapeutics is set to raise up to $146 million through a pro-rata entitlement offer, aiming to accelerate its RNA-based drug candidates targeting major unmet medical needs. Major shareholder support and underwriting commitments underpin the capital raise.

Bass Oil Limited reported a 2.9% increase in total sales revenue for January 2025, driven by steady daily production and notable gains in both the Cooper Basin and Indonesian operations. The company is advancing gas appraisal efforts that could unlock significant new resources.